• Something wrong with this record ?

Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial

FM. Zimmermann, VY. Ding, NHJ. Pijls, Z. Piroth, AHM. van Straten, L. Szekely, G. Davidavicius, G. Kalinauskas, S. Mansour, R. Kharbanda, N. Östlund-Papadogeorgos, A. Aminian, KG. Oldroyd, N. Al-Attar, N. Jagic, JE. Dambrink, P. Kala, O. Angeras,...

. 2023 ; 148 (12) : 950-958. [pub] 20230821

Language English Country United States

Document type Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23016215

BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI. METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke. RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98-1.83]; P=0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6-1.7]; P=0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4-1.7]; P=0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1-2.7]; P=0.02). CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02100722.

Aarhus University Hospital Denmark

Atlanta VA Healthcare System Decatur GA

Cardiovascular Center Aalst Belgium

Catharina Hospital Eindhoven the Netherlands

Centre Hospitalier de l'Université de Montréal Canada

Centre Hospitalier Universitaire de Charleroi Belgium

Clinic of Cardiac and Vascular Diseases Institute of Clinical Medicine Vilnius University Lithuania

Clinical Hospital Centre Zemun University of Belgrade Serbia

Danderyd University Hospital and Karolinska Institutet Solna Sweden

Department of Cardiothoracic Surgery Stanford University CA

Departments of Health Policy and Medicine Stanford University CA

Division of Cardiovascular Medicine and Stanford Cardiovascular Institute Stanford University CA

Emory University School of Medicine Atlanta GA

Golden Jubilee National Hospital Glasgow UK

Gottsegen National Cardiovascular Center Hungary

Houston Methodist Hospital TX

Isala Hospital Zwolle the Netherlands

Karolinska Institutet Solna Sweden

Kings College Hospital London UK

Lausanne University Centre Hospital Switzerland

Medical Faculty of Masaryk University and University Hospital Brno Czech Republic

New York Presbyterian Brooklyn Methodist and Weill Cornell Medical College

Oxford University Hospital NHS Trust UK

Quantitative Sciences Unit Stanford University CA

Rigshospitalet Copenhagen Denmark

Sahlgrenska University Hospital Sweden

Södersjukhuset Hospital Stockholm Sweden

Southlake Regional Health Centre Newmarket Canada

Stanford Center for Clinical Research Department of Medicine Stanford University School of Medicine CA

VA Palo Alto Health Care System CA

Vilnius University Hospital Santaros Klinikos Lithuania

Wythenshawe Hospital Manchester UK

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016215
003      
CZ-PrNML
005      
20231026110155.0
007      
ta
008      
231013s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/CIRCULATIONAHA.123.065770 $2 doi
035    __
$a (PubMed)37602376
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zimmermann, Frederik M $u Catharina Hospital, Eindhoven, the Netherlands (F.M.Z., N.H.J.P., A.H.M.v.S., P.A.L.T.)
245    10
$a Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial / $c FM. Zimmermann, VY. Ding, NHJ. Pijls, Z. Piroth, AHM. van Straten, L. Szekely, G. Davidavicius, G. Kalinauskas, S. Mansour, R. Kharbanda, N. Östlund-Papadogeorgos, A. Aminian, KG. Oldroyd, N. Al-Attar, N. Jagic, JE. Dambrink, P. Kala, O. Angeras, P. MacCarthy, O. Wendler, F. Casselman, N. Witt, K. Mavromatis, SES. Miner, J. Sarma, T. Engstrøm, EH. Christiansen, PAL. Tonino, MJ. Reardon, H. Otsuki, Y. Kobayashi, MA. Hlatky, KW. Mahaffey, M. Desai, YJ. Woo, AC. Yeung, B. De Bruyne, WF. Fearon, FAME 3 Investigators
520    9_
$a BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI. METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke. RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98-1.83]; P=0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6-1.7]; P=0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4-1.7]; P=0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1-2.7]; P=0.02). CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02100722.
650    _2
$a lidé $7 D006801
650    12
$a nemoci koronárních tepen $x chirurgie $7 D003324
650    12
$a frakční průtoková rezerva myokardu $7 D053805
650    _2
$a následné studie $7 D005500
650    12
$a koronární angioplastika $x škodlivé účinky $7 D062645
650    _2
$a koronární bypass $x škodlivé účinky $7 D001026
650    12
$a infarkt myokardu $7 D009203
650    12
$a cévní mozková příhoda $x epidemiologie $x etiologie $7 D020521
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ding, Victoria Y $u Quantitative Sciences Unit (V.Y.D., M.D.), Stanford University, CA $1 https://orcid.org/0000000220499051
700    1_
$a Pijls, Nico H J $u Catharina Hospital, Eindhoven, the Netherlands (F.M.Z., N.H.J.P., A.H.M.v.S., P.A.L.T.)
700    1_
$a Piroth, Zsolt $u Gottsegen National Cardiovascular Center, Hungary (Z.P., L.S.) $1 https://orcid.org/0000000192561267
700    1_
$a van Straten, Albert H M $u Catharina Hospital, Eindhoven, the Netherlands (F.M.Z., N.H.J.P., A.H.M.v.S., P.A.L.T.) $1 https://orcid.org/0009000568476990
700    1_
$a Szekely, Laszlo $u Gottsegen National Cardiovascular Center, Hungary (Z.P., L.S.) $1 https://orcid.org/0000000270404970
700    1_
$a Davidavicius, Giedrius $u Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius University, Lithuania (G.D., G.K.) $u Vilnius University Hospital Santaros Klinikos, Lithuania (G.D., G.K.)
700    1_
$a Kalinauskas, Gintaras $u Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius University, Lithuania (G.D., G.K.) $u Vilnius University Hospital Santaros Klinikos, Lithuania (G.D., G.K.)
700    1_
$a Mansour, Samer $u Centre Hospitalier de l'Université de Montréal, Canada (S.M.)
700    1_
$a Kharbanda, Rajesh $u Oxford University Hospital NHS Trust, UK (R.K.) $1 https://orcid.org/0000000253562395
700    1_
$a Östlund-Papadogeorgos, Nikolaos $u Danderyd University Hospital and Karolinska Institutet, Solna, Sweden (N.Ö.-P.)
700    1_
$a Aminian, Adel $u Centre Hospitalier Universitaire de Charleroi, Belgium (A.A.) $1 https://orcid.org/0000000246679181
700    1_
$a Oldroyd, Keith G $u Golden Jubilee National Hospital, Glasgow, UK (K.G.O., N.A.-A.) $1 https://orcid.org/0000000278423463
700    1_
$a Al-Attar, Nawwar $u Golden Jubilee National Hospital, Glasgow, UK (K.G.O., N.A.-A.)
700    1_
$a Jagic, Nikola $u Clinical Hospital Centre Zemun, University of Belgrade, Serbia (N.J.)
700    1_
$a Dambrink, Jan-Henk E $u Isala Hospital, Zwolle, the Netherlands (J.-H.E.D.)
700    1_
$a Kala, Petr $u Medical Faculty of Masaryk University and University Hospital Brno, Czech Republic (P.K.) $1 https://orcid.org/0000000244169065
700    1_
$a Angeras, Oskar $u Sahlgrenska University Hospital, Sweden (O.A.)
700    1_
$a MacCarthy, Philip $u Kings College Hospital, London, UK (P.M., O.W.)
700    1_
$a Wendler, Olaf $u Kings College Hospital, London, UK (P.M., O.W.)
700    1_
$a Casselman, Filip $u Cardiovascular Center Aalst, Belgium (F.C., B.D.) $1 https://orcid.org/0000000229834215
700    1_
$a Witt, Nils $u Södersjukhuset Hospital, Stockholm, Sweden (N.W.) $u Karolinska Institutet, Solna, Sweden (N.W.)
700    1_
$a Mavromatis, Kreton $u Atlanta VA Healthcare System, Decatur, GA (K.M.) $u Emory University School of Medicine, Atlanta, GA (K.M.) $1 https://orcid.org/0000000172501662
700    1_
$a Miner, Steven E S $u Southlake Regional Health Centre, Newmarket, Canada (S.E.S.M.) $1 https://orcid.org/0000000207833545
700    1_
$a Sarma, Jaydeep $u Wythenshawe Hospital, Manchester, UK (J.S.)
700    1_
$a Engstrøm, Thomas $u Rigshospitalet, Copenhagen, Denmark (T.E.)
700    1_
$a Christiansen, Evald H $u Aarhus University Hospital, Denmark (E.H.C.) $1 https://orcid.org/0000000287404862
700    1_
$a Tonino, Pim A L $u Catharina Hospital, Eindhoven, the Netherlands (F.M.Z., N.H.J.P., A.H.M.v.S., P.A.L.T.)
700    1_
$a Reardon, Michael J $u Houston Methodist Hospital, TX (M.J.R.) $1 https://orcid.org/0000000228806132
700    1_
$a Otsuki, Hisao $u Division of Cardiovascular Medicine and Stanford Cardiovascular Institute (H.O., A.C.Y., W.F.F.), Stanford University, CA
700    1_
$a Kobayashi, Yuhei $u New York Presbyterian Brooklyn Methodist and Weill Cornell Medical College (Y.K.) $1 https://orcid.org/000000016058232X
700    1_
$a Hlatky, Mark A $u Departments of Health Policy and Medicine (M.A.H.), Stanford University, CA $1 https://orcid.org/0000000346869441
700    1_
$a Mahaffey, Kenneth W $u Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, CA (K.W.M.) $1 https://orcid.org/0000000237912148
700    1_
$a Desai, Manisha $u Quantitative Sciences Unit (V.Y.D., M.D.), Stanford University, CA $1 https://orcid.org/0000000269492651
700    1_
$a Woo, Y Joseph $u Department of Cardiothoracic Surgery (Y.J.W.), Stanford University, CA $1 https://orcid.org/000000022506492X
700    1_
$a Yeung, Alan C $u Division of Cardiovascular Medicine and Stanford Cardiovascular Institute (H.O., A.C.Y., W.F.F.), Stanford University, CA
700    1_
$a De Bruyne, Bernard $u Cardiovascular Center Aalst, Belgium (F.C., B.D.) $u Lausanne University Centre Hospital, Switzerland (B.D.) $1 https://orcid.org/000000016567168X
700    1_
$a Fearon, William F $u Division of Cardiovascular Medicine and Stanford Cardiovascular Institute (H.O., A.C.Y., W.F.F.), Stanford University, CA $u VA Palo Alto Health Care System, CA (W.F.F.) $1 https://orcid.org/0000000317991368
710    2_
$a FAME 3 Investigators
773    0_
$w MED00001091 $t Circulation $x 1524-4539 $g Roč. 148, č. 12 (2023), s. 950-958
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37602376 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026110148 $b ABA008
999    __
$a ok $b bmc $g 2000000 $s 1202577
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 148 $c 12 $d 950-958 $e 20230821 $i 1524-4539 $m Circulation (New York, N.Y.) $n Circulation (New York) $x MED00001091
LZP    __
$a Pubmed-20231013

Find record

Citation metrics

Archiving options